Results 111 to 120 of about 79,488 (241)
The receptor tyrosine kinase RET is a Hsp90 client protein and is degraded upon exposure to 17-AAG.
, 2009 Molecular alterations of the receptor tyrosin kinase RET are involved in the pathogenesis of thyroid cancer. Germline point mutations in the extracellular and intracellular domains of the receptor are responsible of a group of inherited cancer diseases ...
Alfano, Luigi
core
C-myc expression in adrenocortical tumours
, 2017 AimsWidespread use of high-resolution imaging techniques and thus increased prevalence of adrenal lesions has made diagnostics of adrenocortical tumours an increasingly important clinical issue. In non-metastatic tumours, diagnosis is based on histology.
Timo Sane +6 more
core +1 more source
VIEW, EarlyView.Abstract Ninety percent of all primary liver malignancies are hepatocellular carcinomas (HCC), making liver cancer the third most common cause of cancer‐associated mortality. Different patterns of programmed cell death (PCD) are crucial for the survival of tumors, and they might serve as a prognostic marker for HCC.
Lin Ding +10 more
wiley +1 more source
Targeting KRAS for cancer therapy
British Journal of Pharmacology, EarlyView.In recent years, therapeutics targeted against KRAS proto‐oncogene GTPase (KRAS)‐mutant cancers have seen significant progress. Herein we outline the biology and epidemiology of KRAS alterations at the lineage and allele levels, reviewing the clinical evidence for KRASG12C inhibition from the discovery of the recessive switch pocket to sotorasib ...
Jianlong Jia +4 more
wiley +1 more source
, 1999 A large body of evidence has been accumulated that demonstrates dominant effects of Myc proto-oncoproteins on different aspects of cellular growth, Myc is one of the few proteins that is sufficient to drive resting cells into the cell cycle and promote ...
Larsson, LG,, Luscher, B,
core
Cancer Science, EarlyView.Lysine acetyltransferase 2A (KAT2A) is a transcriptional coactivator and a member of the Histone Acetyltransferase (HAT) family. While altered KAT2A activity has been implicated in various cancers, its role in bladder cancer (BLCA) remains poorly understood.
Wenjie Yang +8 more
wiley +1 more source
MAPK Inhibitor‐Tolerant Persister Cells in Melanoma: Mechanisms and Therapeutic Vulnerabilities
Cancer Science, EarlyView.Melanoma response to MAPK inhibition progresses from drug‐sensitive cells to drug‐tolerant persister states, which enable survival through adaptive signaling, metabolic rewiring, and phenotypic plasticity. These persister cells serve as an intermediate reservoir from which resistant tumors ultimately emerge. ABSTRACT Though major advancements have been
Bhoomi Shah +3 more
wiley +1 more source
Review: proteins c-Myc and Myc-nick as potential targets for the melignant melanoma treatment
, 2023 Malignant melanoma is the most aggressive and life-threatening skin cancer with increasing incidences over the past decades. Despite accounting for only 4 % of all skin cancers, melanoma confers 80 % of skin cancer induced death.
Selyvanska, I. +5 more
core
Cancer Science, EarlyView.Oncogenic BRAF and KRAS promote global DNA hypomethylation through a directed pathway that increases the levels of TET3, which helps drive tumorigenesis. ABSTRACT Aberrant epigenetic modification is one of the characteristics of the cancer genome.
Ichiro Onoyama +12 more
wiley +1 more source
Targeting Cell Cycle Vulnerabilities in Cancers: Emerging Strategies for Therapeutic Development
Cancer Science, EarlyView.Dysregulated cell cycle control often involves alternative compensatory pathways in cancers to maintain its robustness but provide unique targetable vulnerabilities. We overview recent insights on cancer‐specific vulnerabilities across the cell cycle and discuss how these can be used to develop new therapeutic strategies.
Nana Kamakura +3 more
wiley +1 more source